Insulin glargine
Indication
Type 1 and Type 2 diabetes mellitus
For biosimilars see Insulin glargine biosimilar (Abasaglar®)
Green
Brand:
Lantus®
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Endocrine system
Background
Must be commenced by a healthcare professional who is appropriately trained and experienced in the initiation of insulin.
Insulin glargine 100 units/mL (Lantus®) is recommended for use in patients with type 1 and type 2 diabetes mellitus.
Prescribing should be by brand name, followed by the concentration and recommended daily dose.
Lantus® brand is not a preferred product in the LSCMMG antihyperglycaemics guideline. Biosimilars of Insulin glargine are also available for the treatment of NEW patients and patients assessed to need a medication change. Treatment should normally be started with the least expensive drug.
Recommendation
LSCMMG Recommendation:
Green
Reason for decision:
Suitable for initiation in primary care
Supporting documents: